Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition
US11649237B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 31, 2018 |
| Grant date | May 16, 2023 |
| Priority date | — |
| Expiry date | Aug 31, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein, inter alia, are substituted imidazo[1,5-α]pyrazine compounds, compositions and methods for treating or preventing an IRE1α-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.